Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Mallinckrodt DMD Drug Gets Fast Track Status In The U.S.

Published 08/25/2016, 09:57 PM
Updated 07/09/2023, 06:31 AM

Mallinckrodt Public Limited Company (NYSE:MNK) announced that it has received Fast Track designation in the U.S. for its Investigational New Drug (IND) application for Synacthen Depot for the treatment of patients with Duchenne muscular dystrophy (DMD).

We note that the FDA grants Fast Track status to facilitate the development and quicken the review process for the candidates that are being developed for the treatment of serious conditions that have an unmet medical need.

Synacthen Depot is currently approved and commercialized in ex-U.S. markets for certain autoimmune and inflammatory conditions.

Mallinckrodt revealed that it has initiated a phase I study on the product for the DMD indication.

DMD, a devastating and debilitating disease, represents a market where there is currently no approved drug, indicating significant unmet need for treatments.

We remind investors that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is looking for an approval of its DMD drug, eteplirsen. A New Drug Application (NDA) is currently under review in the U.S.

Moreover, Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is developing its DMD candidate, edasalonexent (CAT-1004), in a phase II (MoveDMD) study. Results from the study are anticipated later this year. Edasalonexent enjoys Orphan drug, Fast Track and Rare Pediatric Disease designation in the U.S. for the treatment of DMD. The candidate also enjoys Orphan Medicinal Product designation for this indication in the EU.

Mallinckrodt currently carries a Zacks Rank #3 (Hold). ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a better-ranked stock in the health care sector, sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .


MALLINCKRODT PL (MNK): Free Stock Analysis Report

SAREPTA THERAP (SRPT): Free Stock Analysis Report

CATABASIS PHARM (CATB): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.